Home Blog Page 2452

HKPC Exhibits at ReThink HK 2025 Embracing Innovative Green Technologies to Promote Sustainable Development across Industries

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 11 September 2025 – Green technologies play a pivotal role in achieving sustainable development. The Hong Kong Productivity Council (HKPC) is participating in ReThink HK 2025, held at the Hong Kong Convention and Exhibition Centre on 11–12 September. Focusing on innovative green technologies, HKPC is presenting a series of groundbreaking applications and business solutions encompassing ESG reporting, sustainability, and carbon neutrality solutions. These initiatives aim to tackle urgent environmental challenges in Hong Kong, such as food waste management, lithium battery recycling, and carbon emissions, while accelerating the green transformation across industries and promoting the practical implementation of more green technology concepts.

As climate change intensifies, the world is increasingly adopting multifaceted strategies to foster a green and low-carbon economy. With robust growth in green technology both globally and in Mainland China, businesses need to seize the opportunity for green transformation. With innovation at its core, HKPC is committed to advancing Hong Kong’s sustainability journey by supporting businesses in developing and adopting innovative green technologies and smart city solutions. These include leveraging artificial intelligence (AI) to enhance smart living and reduce environmental impact. HKPC also offers tailored consultancy services in carbon neutrality and smart living, helping businesses developing feasible carbon reduction targets and plans, exploring low-carbon business opportunities, and supporting their progress towards a green economy and carbon neutrality.

Dr Keith Choy, General Manager of Green Living and Innovation Division of HKPC, said: “HKPC’s participation in ReThink HK once again underscores our commitment to green and smart living as a key development priority. In support of Hong Kong’s sustainable development and the goal of achieving carbon neutrality by 2050, HKPC provides advanced technologies, consulting services, and funding support to empower businesses in reaching their sustainability ambitions. At the expo, we showcased a range of innovative green technologies, including smart food waste management, lithium battery recycling, CO2 capture and utilisation, and hydrogen fuel. Together with our “ESG One” platform, we help businesses effectively utilise resources and set sustainable development goals. We will continue to actively promote green transformation within the industry and build a sustainable future.”

Highlights of HKPC’s innovative green technologies at ReThink HK 2025:

  • Recycling Bin Transporter: An intelligent transport robot, designed specifically for urban food waste recycling and transportation. Utilising automation, AI, and sensor technologies, it enhances operational efficiency and supports smart city and sustainable development goals.
  • PTU2 – Food Waste Pretreatment Unit: A next-generation liquefaction system that converts food waste into slurry for efficient food waste transportation, effectively reducing collection frequency and transportation costs, and promoting a sustainable circular economy.
  • Hydrogen Fuel Innovation: The Centre of Advanced Power and Autonomous Systems (APAS) under HKPC focuses on green transportation, smart mobility, intelligent systems, and emerging applications. At this year’s expo, they showcased a Hydrogen Fuel Cell-electric Off-grid Genset and Type IV Hydrogen Storage Cylinders, providing zero-carbon energy solutions tailored for electric vehicles and pioneering a new direction in e-Mobility.
  • ESG One: A comprehensive platform supporting SMEs in achieving sustainable development goals. It offers free online ESG assessment, consulting services and strategic planning services, enabling green transformation and enhancing ESG brand value.

In addition, the HKPC and APAS participate in two forward-looking seminars, exploring the development and challenges of the low-altitude economy, and the role of waste management in achieving sustainable development and carbon reduction targets in Hong Kong.

HKPC’s “ESG One” is the exclusive co-organiser of the ReThink HK Mainland Business Delegation, offering delegates insights into HKPC’s support services in carbon management, recycling, green technology, smart mobility, and intelligent system development. The event gathered over 20 business leaders and sustainability professionals from Mainland China, fostering interactive exchanges and exploring collaborative opportunities with various stakeholders to promote green technology.

Hashtag: #HKPC #ReThinkHK

The issuer is solely responsible for the content of this announcement.

About Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity excellence through relentless drive of world-class advanced technologies and innovative service offerings to support Hong Kong enterprises. As a nationwide leader in innovative, market-driven research and development (R&D) internationally, specialising in leading technologies and all-rounded manufacturing services, HKPC promotes new industrialisation in Hong Kong and the Greater Bay Area and facilitates the development of new productive forces, leveraging innovation and technology (I&T), as well as bolstering Hong Kong to be an international innovation and technology centre and a smart city. The Council offers comprehensive innovative solutions for Hong Kong industries and enterprises, enabling them to achieve resources and productivity utilisation, effectiveness and cost reduction, and enhance competitiveness in both local and overseas marketplace. The Council partners and collaborates with local industries and enterprises and world-class R&D institutes to develop applied technology solutions for value creation. It also benefits a variety of sectors through product innovation, technology transfer, and commercialisation, bringing enormous business opportunities ahead. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades.

In addition, HKPC offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment, and strengthens talent nurturing and Hong Kong’s competitiveness with FutureSkills training for enterprises and academia to enhance digital capabilities and STEM competencies. For more information, please visit HKPC’s website: .

ChinaAMC signs MOU with Oman Government Delegation

By
Advertorial Desk
-

Previously ChinaAMC teamed with Jabal Asset Management to launch a fund that enabled access to China equity market, making ChinaAMC China’s first mutual fund company to partner with Oman government.

BEIJING, Sept. 11, 2025 /PRNewswire/ — China Asset Management Co. (referred as ChinaAMC below) has signed a Memorandum of Understanding with Oman government delegation comprised of regulator, stock exchanges, sovereign wealth fund and asset manager, on two-way bilateral investment projects, laying the groundwork for further financial cooperation between China, Oman and Gulf States.

The ceremony was held in ChinaAMC’s Beijing office on September 4. The Oman side is represented by senior management from Oman Investment Authority, Mars Development and Investment, Financial Services Authority, Muscat Stock Exchange, Muscat Clearing & Depository, and Jabal Asset Management. Witnessed by senior management from both sides, ChinaAMC CEO Li Yimei and Jabal Asset Management CEO Evgeny Korovin signed the MOU.

ChinaAMC CEO Li Yimei and Jabal Asset Management CEO Evgeny Korovin signed the MOU.
ChinaAMC CEO Li Yimei and Jabal Asset Management CEO Evgeny Korovin signed the MOU.

The ceremony is one leg of Oman government delegation’s five-day China tour, which includes more than 15 high-level meetings across Hong Kong, Shenzhen, Shanghai and Beijing, with Chinese regulators, stock exchanges, sovereign fund and local government, ChinaAMC, CITIC Securities and other top foreign and Chinese financial institutions.

The trip yielded three MOUs, including the one with ChinaAMC.

In late 2024, ChinaAMC teamed with Jabal Asset Management to launch a Loong fund that enabled access to China equity market, making ChinaAMC China’s first mutual fund company to partner with Oman government.

Jabal Asset Management is a wholly-owned subsidiary of Oman government, and Oman Investment Authority is an anchor investor for the Loong Fund.

ChinaAMC representatives have solely advised Oman government delegation on the latest trip and related projects, and have accompanied all meetings.

About ChinaAMC

Founded in April, 1998, China Asset Management is one of the first mutual fund managers in China. Since its inception, ChinaAMC has led the asset management industry with more than two decades of track-record in product innovation. ChinaAMC offers multi-asset investment solutions and one-stop services to investors with various risk-return profiles.

As of June 30, 2025, ChinaAMC’s total AUM exceeded RMB 3.03 trillion (US$423.5 billion), making it one of the largest asset managers in China.

ChinaAMC identifies its core strength as discovering, defining and managing assets, as it offers a balanced mix of asset classes, encompassing equity, fixed income, FOF, REITs, money market,etc. It has been the largest ETF manager in China for 20 consecutive years with an AUM of over RMB 750 billion.

Source: ChinaAMC. AUM includes subsidiaries. Data as of June 30, 2025.

Disclaimer

Investment involves risk, including possible loss of principal. Past performance does not represent future performance. The information contained herein is for reference only and does not constitute an offer or invitation to anyone to invest in any funds and has not been prepared in connection with any such offer.

GLOBAL FIRST “High-Definition Image”: Decoding the “Code of Youth” – LivingPhoenix’s POGMENT Collagen Breakthrough Bridges International Gap

By
Advertorial Desk
-

CHENGDU, China, Sept. 11, 2025 /PRNewswire/ — Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of “collagen fiber bundles” using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen’s self-assembly mechanism.

The result was achieved through collaboration with the Cryo-EM platform team at Tianfu Jincheng Laboratory (Frontier Medical Center). Using a 300kV Cryo-TEM (Titan Krios G4), the team captured ultra-structural details across multiple sample batches, with morphology further validated by Talos L120C TEM at room temperature. This marks a major original breakthrough for China in the high-end biomaterials field.

LivingPhoenix Technology’s POGMENT collagen achieves global first high-resolution visualization of “collagen fiber bundles” by Cryo-EM
LivingPhoenix Technology’s POGMENT collagen achieves global first high-resolution visualization of “collagen fiber bundles” by Cryo-EM

POGMENT is the world’s first biomimetic collagen to overcome thermal instability. It is a synthetic material not derived from animals, solving key bottlenecks in structural stability and functional consistency of traditional collagen. The technology originated from an initial process (1.0) at Kyoto University, was introduced to China (v1.1) by Japanese scientists, upgraded locally in Chengdu to v1.2, and finally developed into a second-generation independent intellectual property system (2.0) by a global team of PhDs from the University of Tokyo, Peking University, Chinese Academy of Sciences, and University Paris Dauphine.

The technology has applied for 6 Chinese invention patents applications and 6 PCT applications, with 3 material patents and 1 use patent already granted. Trademark and other IP rights have been registered in the U.S., EU, UK, South Korea, and Japan. Joint original research by LivingPhoenix, Shanghai Ninth People’s Hospital, National Center of Gerontology Beijing Hospital, Peking University Third Hospital, and the University of Tokyo has been peer-reviewed and published in the Q1 SCI journal Frontiers in Bioengineering and Biotechnology (Impact Factor: 4.8).

Furthermore, this technological achievement has been filed with the National Medical Products Administration (NMPA) in accordance with national standards, and has been included in the Terminology for Collagen in Tissue-Engineered Medical Devices (YY/T1955-2025), Medical Device Master File and Cosmetic Ingredient.

For collaboration opportunities in cosmetics, medical aesthetics, or high-end biomaterials, contact:

Email: POGMENT@mylivingphoenix.com 

Official website：www.mylivingphoenix.com  

TARIFF FEARS DRIVE U.S. STOCKPILING IN AUGUST, WHILE MANUFACTURING WEAKENS IN EUROPE AND ASIA: GEP SUPPLY CHAIN VOLATILITY INDEX

By
Advertorial Desk
-
  • North America’s supply chains get busier, with sharp stockpiling of components to guard against tariff-driven shortages and price inflation
  • Asia’s manufacturers cut purchases, led by Japan and Taiwan, and to a lesser extent China
  • Europe weakens further, dragged down by Germany and a sharp downturn in the UK

CLARK, N.J., Sept. 11, 2025 /PRNewswire/ — GEP Global Supply Chain Volatility Index, a leading economic indicator based on a monthly survey of 27,000 businesses, slipped to -0.39 in August, from -0.35 in July, signaling rising spare capacity as global supply chain activity cooled.

The global figure concealed stark regional contrasts. North America was the outlier, with supply chains running close to full capacity as companies in the continent stockpiled raw materials and components to protect against tariff-driven shortages and delivery delays. This was particularly true for the US consumer goods sector, which includes industries such as food & beverages and household products.

By contrast, Asia’s index fell to a three-month low as purchasing activity weakened in China’s consumer non-cyclicals sector, although the region’s weakness was predominantly across Japan and Taiwan. Europe also deteriorated, with Germany’s basic materials sector faltering and UK manufacturing plunging deeper into contraction. The index here (-0.90) signaled one of the steepest declines since 2024.

“So far tariffs have neither spurred growth nor triggered collapse,” said Michael DuVall, GEP’s global head of supply chain strategy. “Tariff uncertainty is no longer a temporary, it’s a structural reality in the supply chain. Companies need to manage it by reinvesting in resilience, diversifying suppliers, and building critical capabilities like demand sensing to make faster, smarter decisions.”

GEP Global Supply Chain Volatility Index
GEP Global Supply Chain Volatility Index

Interpreting the data:
Index > 0, supply chain capacity is being stretched. The further above 0, the more stretched supply chains are.
Index < 0, supply chain capacity is being underutilized. The further below 0, the more underutilized supply chains are.

REGIONAL HIGHTLIGHTS

  • ASIA: Index fell to a three-month low to indicate rising spare capacity across Asia’s supply chains as purchasing volumes in China was flat. In contrast, South Korea, Indonesia and particularly India saw greater factory procurement activity.
  • NORTH AMERICA: Supply chains were practically running at full capacity as recent orders were delivered and companies added to stock.
  • EUROPE: Index falls again as factories purchased fewer intermediate goods and destocked. The data continue to highlight the fragile nature of Europe’s industrial recovery.
  • U.K.: Index falls sharply to -as U.K. manufacturers cutback on procurement and inventories.
GEP Global Supply Chain Volatility Index
GEP Global Supply Chain Volatility Index

Interpreting the data:
Index > 0, supply chain capacity is being stretched. The further above 0, the more stretched supply chains are.
Index < 0, supply chain capacity is being underutilized. The further below 0, the more underutilized supply chains are.

For more information, visit www.gep.com/volatility.

Note: Full historical data dating back to January 2005 is available for subscription. Please contact economics@spglobal.com.

The next release of the GEP Global Supply Chain Volatility Index will be 8 a.m. ET, Oct. 10, 2025.

About the GEP Global Supply Chain Volatility Index 
The GEP Global Supply Chain Volatility Index is produced by S&P Global and GEP. It is derived from S&P Global’s PMI® surveys, sent to companies in over 40 countries, totaling around 27,000 companies. The headline figure is a weighted sum of six sub-indices derived from PMI data, PMI Comments Trackers and PMI Commodity Price & Supply Indicators compiled by S&P Global.

  • A value above 0 indicates that supply chain capacity is being stretched and supply chain volatility is increasing. The further above 0, the greater the extent to which capacity is being stretched.
  • A value below 0 indicates that supply chain capacity is being underutilized, reducing supply chain volatility. The further below 0, the greater the extent to which capacity is being underutilized.

A Supply Chain Volatility Index is also published at a regional level for Europe, Asia, North America and the U.K. For more information about the methodology, click here.

About GEP
GEP® delivers AI-powered procurement and supply chain solutions that help global enterprises become more agile and resilient, operate more efficiently and effectively, gain competitive advantage, boost profitability and increase shareholder value. Fresh thinking, innovative products, unrivaled domain expertise, smart, passionate people — this is how GEP SOFTWARE™, GEP STRATEGY™ and GEP MANAGED SERVICES™ together deliver procurement and supply chain solutions of unprecedented scale, power and effectiveness. Our customers are the world’s best companies, including more than 1,000 Fortune 500 and Global 2000 industry leaders who rely on GEP to meet ambitious strategic, financial and operational goals. A leader in multiple Gartner Magic Quadrants, GEP’s cloud-native software and digital business platforms consistently win awards and recognition from industry analysts, research firms and media outlets, including Gartner, Forrester, IDC, ISG, and Spend Matters. GEP is also regularly ranked a top procurement and supply chain consulting and strategy firm, and a leading managed services provider by ALM, Everest Group, NelsonHall, IDC, ISG and HFS, among others. Headquartered in Clark, New Jersey, GEP has offices and operations centers across Europe, Asia, Africa and the Americas. To learn more, visit www.gep.com.

About S&P Global
S&P Global (NYSE: SPGI) S&P Global provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make decisions with conviction. From helping our customers assess new investments to guiding them through ESG and energy transition across supply chains, we unlock new opportunities, solve challenges and accelerate progress for the world. We are widely sought after by many of the world’s leading organizations to provide credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help the world’s leading organizations plan for tomorrow, today.

Media Contacts

Derek Creevey                                                           

Joe Hayes

Director, Public Relations                                           

Principal Economist

GEP                                                                           

S&P Global Market Intelligence

Phone: +1 646-276-4579                                             

Phone: +44-1344-328-099

Email: derek.creevey@gep.com                                   

Email: joe.hayes@spglobal.com

 

Locksley Resources Adds 249 Additional Claims to Landholding of More than 40 sq km of Highly Prospective Critical Minerals Ground in California’s Mojave Region

By
Advertorial Desk
-

Brings Company’s Total Claims to 491 in Area Housing the Only Rare Earths Producing Mine in U.S.

Move Expands Locksley’s Exploration Pipeline Across Antimony, Rare Earths Elements and Polymetallic Prospects

SAN BERNARDINO, Calif., Sept. 11, 2025 /PRNewswire/ — Locksley Resources Limited (ASX: LKY; OTCQB: LKYRF), announced it has significantly expanded its strategic footprint within the Mojave Critical Minerals Corridor in California through the staking of an additional 249 claims. This brings the company’s total landholding to 491 claims.

The new claims are adjacent to Locksley’s existing tenement position and adjoin MP Materials landholding, which includes the Mountain Pass Rare Earth Mine. The new claims also secure additional acreage for Locksley in that they abut the recently identified antimony, rare earths elements (REEs) and polymetallic mineralization reported by the company.

“These additional claims significantly strengthen Locksley’s competitive positioning within one of the most prospective critical minerals regions in the U.S.,” said Nathan Lude, Head of Strategy, Capital Markets and Commercialization for the company. “With demand for antimony and REEs underpinned by U.S. supply chain security initiatives, the expanded landholding provides Locksley with a broader platform to advance multiple exploration and development opportunities,” he noted.

The south-east claims encompass the favorable gneissic geology, which hosts the Mountain Pass mine and carbonatites. “Significantly there are substantial regional north to north-west striking structures evident in the magnetic geophysics datasets,” said Julian Woodcock, Locksley’s technical director. “These transgress across the areas staked, which conceptually have the potential to host pathways for REE bearing carbonatites and be related to other styles of mineralization,” he said.

Woodcock added that the Northern claims are 3km directly along strike from Dateline Resources Colosseum Gold Project. “In addition, the USGS geochemical database indicates polymetallic and precious metals occurrences in the area immediately adjoining the new northern claims. As such there are multiple commodity opportunities evident within this claim area.”

Lude added, “Importantly, several of the new claims directly adjoin the Mountain Pass larger claim package, underlining the strategic significance of Locksley’s footprint within the corridor. This positioning enhances potential for both exploration discovery and long-term commercialization pathways, including downstream processing partnerships in line with U.S. government priorities for supply chain resilience.”

More information on this can be found at https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02992119-6A1283295&v=c2533a54e2514fb77a8f93f84db686e1125273e9.

Locksley Resources is an Australian-based explorer focused on critical minerals and base metals, with assets in both the U.S. and Australia. The company is actively advancing its U.S. asset, the Mojave Project, in California, targeting rare earth elements (REEs) and antimony. The company has also announced a strategic collaboration with Rice University to develop DeepSolv™, for domestic processing of North American antimony. The agreement is the first step in the initiation of Locksley’s U.S. Critical Minerals and Energy Resilience Strategy to accelerate “mine-to-market” deployment of antimony in the U.S.

Contact: Beverly Jedynak, Beverly.jedynak@viriathus.com, 312-943-1123; 773-350-5793 (cell)

YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

By
Advertorial Desk
-

SHANGHAI, Sept. 11, 2025 /PRNewswire/ — YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech’s clinical programs and global strategic execution.

Dr. Yuxuan Wu, Founder and CEO of YolTech, “This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide.”

About YolTech Therapeutics
Founded in 2021, YolTech Therapeutics is advancing next-generation in vivo gene-editing therapies designed for one-time treatment. The company has built a fully integrated platform encompassing proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a cutting-edge lipid nanoparticle delivery system (Yol-LNPs), enabling precise, efficient, and tissue-specific gene editing across a broad range of therapeutic areas.

In 2024, YolTech’s lead program YOLT-201, a CRISPR-based therapy for transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in China to enter Phase I/IIa clinical trial. Since then, the company has advanced four clinical-stage programs addressing ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD).

YolTech operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up, ensuring manufacturing consistency and scalability across programs.

With one of the most extensive in vivo gene-editing clinical pipeline globally, YolTech continues to lead in the field. Its base-editing therapy YOLT-101, developed for familial hypercholesterolemia (HeFH), became the first in vivo base-editing program to receive IND clearance in both China and the United States.

 

Commerce Dot Com Wins Double Honours At PIKOM Digital Excellence Awards 2025

By
Advertorial Desk
-

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 11 September 2025 – Commerce Dot Com Sdn Bhd (CDC) has achieved a remarkable double victory at the PIKOM Digital Excellence Awards 2025 (PDEA), winning recognition for both its transformative digital solutions and its commitment to cybersecurity. The company was awarded the Outstanding Digital Transformation Project (Corporate Category) which was received by Ministry of Finance (MOF) for its flagship platform, ePerolehan, as well as the coveted Cybersecurity Award.

Executive Chairman of CDC, Syed Azmin Syed Nor (second from right), receiving the Cybersecurity Award from Minister of Digital YB Gobind Singh Deo at the PIKOM Digital Excellence Awards (PDEA) 2025 Gala Dinner in Sunway Resort Hotel.
Executive Chairman of CDC, Syed Azmin Syed Nor (second from right), receiving the Cybersecurity Award from Minister of Digital YB Gobind Singh Deo at the PIKOM Digital Excellence Awards (PDEA) 2025 Gala Dinner in Sunway Resort Hotel.

The ePerolehan system, Malaysia’s official electronic procurement platform under the custodian of MOF, has been at the heart of the nation’s digitalisation journey since its launch in 2000. Over the past 25 years, it has evolved from a pioneer government electronic procurement initiative into a benchmark for large-scale IT transformation, reshaping how government procurement is managed and delivered. Today, ePerolehan connects thousands of suppliers with government agencies, enabling greater transparency, efficiency, and accountability across the public sector.

Winning the Outstanding Digital Transformation Project Award affirms ePerolehan’s pivotal role in advancing Malaysia’s knowledge-based economy through continuous innovation, effective change management, and strong stakeholder engagement. The Cybersecurity Award further underscores CDC’s commitment to resilience, with ePerolehan built on security-by-design principles that safeguard sensitive data and critical infrastructure. In today’s climate of growing cyber threats, these dual recognitions highlight ePerolehan’s enduring impact as a national platform that delivers innovation, reliability, and long-term socio-economic value.

“Digital transformation and cybersecurity are inseparable. Winning both awards is a reminder of our responsibility to lead with innovation while safeguarding trust. Our journey with ePerolehan is far from over – we are committed to building platforms that are future-ready and continue to serve with transparency and resilience.” said Syed Azmin Syed Nor, Executive Chairman of CDC.

The dual awards reflect CDC’s vision that true digital transformation must go hand in hand with robust cybersecurity. By combining cutting-edge innovation with uncompromising standards of trust, CDC has built a platform that supports government, empowers businesses, and benefits citizens nationwide.

Group photo of CDC and MOF at the PDEA 2025 Gala Dinner at Sunway Resort Hotel.
Group photo of CDC and MOF at the PDEA 2025 Gala Dinner at Sunway Resort Hotel.

PDEA 2025, Malaysia’s premier digital excellence awards, honours visionary companies and leaders who are shaping innovation and driving impact across the nation’s tech ecosystem. The awards were chosen by professional jury comprising senior industry experts.

Hashtag: #CDC #CommerceDotCom #PDEA #PIKOM




The issuer is solely responsible for the content of this announcement.

About Commerce Dot Com Sdn Bhd

Commerce Dot Com Sdn Bhd (CDC), established in 1999, pioneered ePerolehan, Malaysia’s electronic government Procurement system under the Ministry of Finance. For 25 years, CDC has driven digital transformation in public procurement, fostering transparency, accountability, and inclusivity, and continues to be a trusted technology partner for the nation.

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

By
Advertorial Desk
-

SYDNEY, Sept. 11, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.

In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia’s investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved a complete (100%) disruption of circulating tumor cell (CTC) clusters containing three or more cells.”

Key Points

  • HER2-positive breast cancer accounts for 15–20% of cases and remains a clinical challenge despite the transformative impact of HER2-targeted therapies, with many patients experiencing resistance, recurrence, or metastasis.
  • Immunotherapy has demonstrated success across several solid tumors but has shown limited efficacy in HER2-positive breast cancer, underscoring the need for new therapeutic approaches.
  • In this study, liquid biopsy profiling of Stage IV patients revealed that paxalisib treatment effectively disrupted CTCs and CTC clusters, which are considered biomarkers of aggressive disease and metastasis.
  • Immunofluorescence analyses showed that paxalisib-treated blood samples from HER2-positive mBC patients achieved complete disruption of highly metastatic CTC clusters (≥3 cells).

“This monotherapy ex-vivo result extends our understanding of paxalisib’s potential beyond triple-negative breast cancer into HER2-positive disease,” said Dr. John Friend, CEO of Kazia Therapeutics. “The ability to disrupt circulating tumor cell clusters, which are strongly associated with metastasis and poor prognosis, represents a transformative therapeutic avenue. We are particularly excited by the precision medicine aspect of this work, which leverages biomarkers to both track metastatic burden and guide therapeutic decisions. This work underscores Kazia’s commitment to expanding paxalisib’s utility across multiple subtypes of advanced breast cancer, addressing high unmet need in patients with limited options.”

These findings complement Kazia’s ongoing Phase 1b trial in Stage IV triple-negative breast cancer (TNBC), where initial patient data announced in July 2025 demonstrated significant reductions in circulating tumor cells and clusters, underscoring the broader potential of paxalisib to address metastatic progression across multiple breast cancer subtypes.

Next Steps

Detailed datasets encompassing metastatic signatures and disrupted progenitor populations in Stage IV HER2-positive breast cancer have been submitted for presentation at an upcoming global oncology meeting in 2025.

For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC,  Astarr@lifesciadvisors.com, +1-201-786-8795.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia’s clinical and preclinical trials, including the potential presentation at an oncology conference of comprehensive datasets, including analyses of metastatic signatures and disrupted progenitor populations in Stage IV HER2-positive breast cancer patients, Kazia’s strategy and plans with respect to its paxalisib program, the potential results of its Phase 1b clinical trial evaluating paxalisib in combination with olaparib or pembrolizumab for patients with advanced breast cancer, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

This announcement was authorized for release by Dr John Friend, CEO

1...2,4512,4522,453...6,466Page 2,452 of 6,466